Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicifadine SCHEMBL10235464 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520915 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL6003632 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL14520900 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL5436336 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL121607 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL5443365 | 0.98 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Bicifadine SCHEMBL1438038 | 0.96 | SLC6A2 (0.93) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL26938717 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL30272554 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2141 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-118782152-B | Organic heterocyclic biomarker for wild and cultivated four-large family fish population and application thereof | 中国水产科学研究院长江水产研究所 | 2025-05-20 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118324651-A | Preparation method and application of chiral amide | 中国科学技术大学 | 2024-07-12 | — | — | CN | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230285387-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220023292-A1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLOGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY | CONCERT PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| US-20040132826-A1 | Modified release compositions of milnacipran | COLLEGIUM PHARMACEUTICAL, INC. | 2004-07-08 | — | — | US | claimed |
| US-20040121010-A1 | once-a-day oral milnacipran pulsatile release when administered orally, releases drug in spaced apart \"pulses\", this delivery profile reduces gastrointestinal side effects by minimizing exposure of the internal mucosal surfaces to the drug | COLLEGIUM PHARMACEUTICAL, INC. | 2004-06-24 | — | — | US | claimed |
| US-20040122104-A1 | Modified release compositions of milnacipran | COLLEGIUM PHARMACEUTICAL, INC. | 2004-06-24 | — | — | US | claimed |
| WO-2004043920-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | EUTHYMICS BIOSCIENCE, INC. | 2004-05-27 | — | — | US | claimed |
| WO-2004039361-A1 | PULSATILE RELEASE COMPOSITIONS OF MILNACIPRAN | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2004039320-A2 | STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2004037190-A2 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-6204284-B1 | ALCOHOL OR COCAINE ABUSE | AMERICAN CYANAMID COMPANY | 2001-03-20 | — | — | US | claimed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | claimed |